Get the Stockscreener App
0.613
1.16%
0.007
After Hours:
.60
-0.013
-2.12%
Dbv Technologies Adr stock is traded at $0.613, with a volume of 327.49K.
It is up +1.16% in the last 24 hours and down -29.26% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
See More
Previous Close:
$0.606
Open:
$0.6299
24h Volume:
327.49K
Relative Volume:
0.50
Market Cap:
$58.30M
Revenue:
-
Net Income/Loss:
$-102.09M
P/E Ratio:
-1.1045
EPS:
-0.555
Net Cash Flow:
$-108.72M
1W Performance:
+20.67%
1M Performance:
-29.26%
6M Performance:
-49.72%
1Y Performance:
-61.12%
1-Day Range:
$0.54
$0.6299
1-Week Range:
$0.4501
$0.6481
52-Week Range:
$0.4409
$2.14
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
0.613 | 58.30M | 0 | -102.09M | -108.72M | -0.555 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
European Equities Traded in the US as American Depositary Decline in Tuesday Trading - MSN
Dbv technologies chief medical officer sells shares worth $1,269 - Investing.com
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com - Defense World
DBV Technologies (STU:DBV0) Shares Outstanding (EOP) : 96.20 Mil (As of Sep. 2024) - GuruFocus.com
DBV Technologies (STU:DBV0) Financial Strength : 7 (As of Sep. 2024) - GuruFocus.com
DBV Technologies (STU:DBV0) 3-Year EBITDA Growth Rate : 29.70% (As of Sep. 2024) - GuruFocus.com
DBV Technologies (STU:DBV0) 3-Year FCF Growth Rate : 32.90% (As of Sep. 2024) - GuruFocus.com
European Equities Traded in the US as American Depositary Decline Slightly in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Fall Sharply in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading - MSN
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week - MSN
European Equities Traded in the US as American Depositary Rise Thursday - MSN
StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT) - Defense World
DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
DBV Technologies Stock Set to Reverse Split on Friday, November 29th (NASDAQ:DBVT) - MarketBeat
DBV Technologies Stock to Reverse Split on Friday, November 29th (NASDAQ:DBVT) - Defense World
DBV Technologies Announces Plan to Implement ADS Ratio Change - The Manila Times
DBV Technologies Plans 1:5 ADS Ratio Change to Meet Nasdaq Requirements | DBVT Stock News - StockTitan
DBV Technologies’ stock slides as financial woes worsens - Pharmaceutical Technology
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - MSN
DBV Technologies Reports Third Quarter 2024 Financial Results - GlobeNewswire
DBV Technologies (NASDAQ:DBVT) Stock Price Passes Above 50 Day Moving AverageTime to Sell? - MarketBeat
DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com - Defense World
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - MSN
DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com - Defense World
DBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.com - MarketBeat
European Equities Traded in the US as American Depositary Receipts Gain Wednesday - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading - MSN
HC Wainwright Forecasts Higher Earnings for DBV Technologies - Defense World
European Equities Traded in the US as American Depositary Receipts Rise Slightly Higher in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading - MSN
Data-Based Insights About DBV Technologies ADR (DBVT) - Stocks Register
HC Wainwright Has Positive Forecast for DBVT FY2024 Earnings - MarketBeat
GSK Plc ADR (GSK): An Important Analyst Insights - Stocks Register
Paramount Global (NASDAQ: PARA): Blank Check On Growth? - Stocks Register
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading - MSN
H.C. Wainwright raises DBV Technologies shares price target, keeps Buy rating - Investing.com India
DBV Technologies (NASDAQ:DBVT) PT Raised to $7.00 - MarketBeat
The United States Allergy Immunotherapy Market Size & Outlook, 2027 - Grand View Research
DBV Technologies ADR (NASDAQ: DBVT) Is The Number One Stock Currently Moving. - Stocks Register
Atlantic Union Bankshares Corp Still Hasn’t Convinced Analysts? - Stocks Register
H.C. Wainwright & Co. Raises Price Target on Biotech Following Positive Regulatory Updates - Streetwise Reports
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe - GlobeNewswire
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dbv Technologies Adr Stock (DBVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
Jul 29 '24 |
Sale |
0.98 |
1,785 |
1,749 |
79,367 |
| Mohideen Pharis | Chief Medical Officer |
May 24 '24 |
Sale |
1.36 |
660 |
898 |
81,152 |
| Mohideen Pharis | Chief Medical Officer |
May 22 '24 |
Sale |
1.38 |
382 |
527 |
81,812 |
| Tasse Daniel | CHIEF EXECUTIVE OFFICER |
Mar 08 '24 |
Buy |
0.83 |
17,094 |
14,188 |
17,094 |
| Ndu Adora | Director |
Feb 06 '24 |
Buy |
0.89 |
1,825 |
1,624 |
1,825 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):